Sangamo Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sangamo Therapeutics, Inc.
The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.
Pfizer CEO Albert Bourla discussed the emergency use authorization filing for Paxlovid, expanding access to the COVID-19 pill in lower income countries and booster shots, at the STAT Summit.
Ardelyx will add to FDA’s growing dispute resolution queue with plan to appeal tenapanor complete response letter; Avenue Therapeutics’ IV tramadol dispute resolution tops out with FDA plea for advisory committee advice.
Base editing has reached a new milestone as Beam’s lead candidate gets the green light for clinical trials, and its peer Verve Therapeutics is not far behind, while big pharma dips its toes in the water.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Ceregene, Inc
- Sangamo Biosciences, Inc.
- TxCell S.A.